Subtype
Adrenal Gland Pheochromocytoma
CI-CAN-00004340PCCExplore in graph →
Non-malignant27 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004340PCCExplore in graph →
Clinical trials
127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004847 | Diagnosis of Pheochromocytoma | recruiting | Phase 1 | 3,000 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 |
| Sep 18, 2026 |
| clinicaltrials |
| NCT04394858 | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer | active not recruiting | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT03206060 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06377033 | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | recruiting | N/A | 1,000 | University of PennsylvaniaOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07714551 | Zanzalintinib in Unresectable and Progressive MPGGs | not yet recruiting | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07538791 | Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)(PRRT-PGL-PHEO) | not yet recruiting | — | 210 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07680205 | An Experimental Study of Belzutifan Impact on Catecholamine Metabolism | recruiting | Phase 2 | 12 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07661420 | 211At-MABG in Adults With Advanced Neuroendocrine Cancers | not yet recruiting | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03541720 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | active not recruiting | Early Phase 1 | 13 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00107289 | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | recruiting | Phase 2 | 200 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT00669266 | Adrenal Tumors - Pathogenesis and Therapy | recruiting | — | 500 | University of WuerzburgOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07516275 | Prospective Cohort Study of Pheochromocytoma/Paraganglioma | not yet recruiting | — | 200 | Peking Union Medical College HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03839498 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | active not recruiting | Phase 2 | 6 | Columbia UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03946527 | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)(LAMPARA) | active not recruiting | Phase 2 | 10 | Antonio FojoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05636540 | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | recruiting | Early Phase 1 | 30 | Heather WachtelOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT06573723 | Institutional Registry of Rare Diseases | recruiting | — | 380 | Hospital Italiano de Buenos AiresOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03160274 | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | recruiting | — | 2,000 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT07200245 | Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors(HEMODYNAMICS) | not yet recruiting | — | 522 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07195500 | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma | recruiting | — | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06813742 | 18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma | recruiting | — | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05702944 | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | recruiting | Phase 4 | 24 | Seoul National University HospitalOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06429397 | Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma | not yet recruiting | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06444607 | Hereditary Pheochromocytoma Assessment of Tumour Immunologies(HEPHESTOS) | recruiting | — | 200 | Radboud University Medical CenterOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC(LUFOR) | recruiting | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05446779 | Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death(SuddenDeath) | active not recruiting | — | 400 | Helsinki University Central HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04788927 | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study(PPGL-Pred) | not yet recruiting | — | 400 | Rigshospitalet, DenmarkOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03344016 | Multicenter Pheochromocytoma and Paraganglioma Evaluation(MUPPET) | recruiting | N/A | 1,148 | Felix BeuschleinOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03474237 | A Prospective Cohort Study for Patients With Adrenal Diseases | enrolling by invitation | — | 1,500 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials